Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase - Wikidata - awgldk - TriplyDB

Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase

Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase

http://www.wikidata.org/entity/Q34066537

about

Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy Molecular characterization of ambiguous mutations in HIV-1 polymerase gene: implications for monitoring HIV infection status and drug resistance Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.First line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter study Stability of HIV-1 Nucleic Acids in Dried Blood Spot Samples for HIV-1 Drug Resistance Genotyping Use of a high resolution melting (HRM) assay to compare gag, pol, and env diversity in adults with different stages of HIV infection A Rough Set-Based Model of HIV-1 Reverse Transcriptase Resistome PAPNC, a novel method to calculate nucleotide diversity from large scale next generation sequencing data.Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy.Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.Computational Analysis of Molecular Interaction Networks Underlying Change of HIV-1 Resistance to Selected Reverse Transcriptase Inhibitors.Characterization of HIV-1 RNA forms in the plasma of patients undergoing successful HAART.Patterns of Human Immunodeficiency Virus type 1 recombination ex vivo provide evidence for coadaptation of distant sites, resulting in purifying selection for intersubtype recombinants during replication.Minority variants of drug-resistant HIV.Subtype-associated differences in HIV-1 reverse transcription affect the viral replication.Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.HIV-1 continues to replicate and evolve in patients with natural control of HIV infection Single cell analysis of lymph node tissue from HIV-1 infected patients reveals that the majority of CD4+ T-cells contain one HIV-1 DNA molecule.PolyAna: analyzing synonymous and nonsynonymous polymorphic sites.Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule.Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy Longitudinal Genetic Characterization Reveals That Cell Proliferation Maintains a Persistent HIV Type 1 DNA Pool During Effective HIV Therapy.Ex vivo activation of CD4+ T-cells from donors on suppressive ART can lead to sustained production of infectious HIV-1 from a subset of infected cells Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoir Ultrasensitive allele-specific PCR reveals rare preexisting drug-resistant variants and a large replicating virus population in macaques infected with a simian immunodeficiency virus containing human immunodeficiency virus reverse transcriptase.Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals.HIV populations are large and accumulate high genetic diversity in a nonlinear fashion Rapid genotyping using pyrene-perylene locked nucleic acid complexes.Broad activation of latent HIV-1 in vivo.Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy.Novel (phenylethynyl)pyrene-LNA constructs for fluorescence SNP sensing in polymorphic nucleic acid targets.Amplifying and quantifying HIV-1 RNA in HIV infected individuals with viral loads below the limit of detection by standard clinical assays.No evidence of HIV replication in children on antiretroviral therapy.Single-cell analysis of HIV-1 transcriptional activity reveals expression of proviruses in expanded clones during ART.HIV-1 Virion Production from Single Inducible Proviruses following T-Cell Activation Ex Vivo.

P2860

Q28475150-1B32CFEB-B0A8-41A6-8272-B437752672D0 Q28487475-B528BB15-6655-4779-8B30-4549584DC340 Q28534497-47157C0A-DDE6-4C14-8752-58770B1249A8 Q28537694-ADD3B3E1-7011-497A-9299-AB2CB970A4BE Q28538326-3D10C24A-CB10-4B47-BD1C-57C615E96239 Q28546274-ABF7CD95-2FE9-4505-A659-5D4872A8B2C4 Q28743210-45D2FBA8-2847-45AA-A191-8FA17D647965 Q30492811-A68B90E7-56CC-4022-A19A-7D5FFC430598 Q30788601-000EDB6B-C5E8-48FA-BB49-ED1870D5EB74 Q33455862-145B12A3-C2C8-4205-914A-FF792F311698 Q33514943-158557B8-5AEB-4130-987E-F4E07B5D8957 Q33714377-31DA143F-C3B7-41BD-90DE-A89B43428A7B Q33793189-8FABFFC1-A0B7-424F-A8D0-F832333C4786 Q33892114-41592D2B-E73E-4248-8435-4EF340497702 Q33964088-A790078E-6B4B-4376-8993-915A50DAC157 Q34047780-1C3C8C43-22E5-49A6-A458-3C81F9B8B6EB Q34243467-2CA275F5-BADF-4252-8897-75CB421CF5D1 Q34303603-CB54E1CC-3830-4EBE-B579-CD0FAAD99B88 Q34416428-902838CE-DB48-420B-BB1B-8FC03CCBF246 Q34789289-D793BD65-09EB-475C-A6E7-3E0D04E98939 Q35072675-097800D3-6F32-4869-95B1-57802BAA67C5 Q35091012-6DABC495-44CC-4609-9848-94D6844052EC Q35126342-A4F87D91-23BF-49A2-8F65-750DBF38E4CC Q35965172-4474D59E-972E-491F-BFD2-D21383D5C733 Q36287580-F92A58F4-0A7B-47CD-9E4E-906EEA7A7D63 Q36318184-81104E20-7386-4CE0-B818-96E5547BB2A0 Q36397557-1587237F-F64C-445A-9C5F-7DFECAAE7F06 Q36481572-92B5916D-EED8-4611-81C3-6CC890C24D0A Q36501787-D7C8EC90-B074-4BDB-9C23-73E469DA6FD6 Q37110723-951F1A6B-7AF5-45A1-8989-EB37CDAE5161 Q37123158-281A8E24-C9B0-4D4A-94DA-62410C1443CE Q37167992-C69A6909-735C-419F-AC14-DC73030D0ABB Q37260309-7F90305C-E157-4882-9F5A-5FB4399D7F66 Q37582339-A8478658-3028-4AF2-BE4E-93E3026EB7C1 Q37719759-25300CE0-84B5-4E73-A69E-D9E5B9E24282 Q38323911-F262E02B-8D9B-4A67-BA3E-5797CB6CA92C Q39585950-EC8F6718-2FCA-47C0-AC37-3B9D9E5D988F Q40047983-76F95FB9-15F2-4B6A-86DC-54B4429EA154 Q40239429-F490E852-7E29-4BBC-BB87-D040F5E3C751 Q40913388-C14DC2C1-4035-41E2-B55F-9B0304831020

P2860

Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase

http://www.wikidata.org/entity/Q34066537

description

2008 nî lūn-bûn

@nan

2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Frequent polymorphism at drug ...... ease and reverse transcriptase

@ast

Frequent polymorphism at drug ...... ease and reverse transcriptase

@en

Frequent polymorphism at drug ...... ease and reverse transcriptase

@nl

type

label

Frequent polymorphism at drug ...... ease and reverse transcriptase

@ast

Frequent polymorphism at drug ...... ease and reverse transcriptase

@en

Frequent polymorphism at drug ...... ease and reverse transcriptase

@nl

prefLabel

Frequent polymorphism at drug ...... ease and reverse transcriptase

@ast

Frequent polymorphism at drug ...... ease and reverse transcriptase

@en

Frequent polymorphism at drug ...... ease and reverse transcriptase

@nl

P1433

Q34066537-627A9BAB-11C2-48A8-ADDC-33069C94705C

P1476

Q34066537-EDCB015A-60CD-4CA9-BA0C-79D5CE96FEF3

P2093

Q34066537-088EFFB9-9CD6-416A-A977-E9D990EAA6FF

Q34066537-095BEB91-D83A-48C6-9698-849A4D9669C3

Q34066537-856CE87E-A5D6-417B-831A-1A25D9F3BF65

Q34066537-885278D6-6109-40B6-861B-71B0F01671AA

Q34066537-96DCECD0-68A7-4FE1-ADC8-C35BFBD712F1

Q34066537-D995FD7A-FE94-4539-A90D-AF434278FB55

Q34066537-E06D5790-AE39-44F4-BFCC-CFDA1507FBE5

Q34066537-EA104884-9F00-4C6C-882E-E680BD864BA9

P2860

Q34066537-251FAE4C-68B5-4A68-9684-697A96A67DD5

Q34066537-3F6AC320-76BF-4BF3-927C-ED496061C20E

Q34066537-5AF542B5-44DD-44FE-A102-E15869C60271

Q34066537-89F39F8D-F301-45B8-B361-D308AA2A85E6

Q34066537-A9E81FD2-3697-4E96-B596-74EE9AB0748B

Q34066537-AA4C9DE4-F936-4F24-AAD6-FA1770921333

Q34066537-AF786150-E1F6-43D6-A697-91E8F6122A64

Q34066537-C27E69A3-B731-4060-99D2-E866D7B39A2C

Q34066537-DF47AAF2-EC15-45FF-AF32-E58E345CC163

Q34066537-EFA36BF2-1B54-4AB8-921C-1F05A9BF16FF

P304

Q34066537-3FB0C11A-AA9A-4853-8808-8C39E822C088

P31

Q34066537-68A1FC0A-3ED3-4579-82B3-3806BFE1C598

P356

Q34066537-ACB52079-6AD8-4A7E-AEFC-A0C79D3FA396

P407

Q34066537-3351F703-8D0D-4BB3-8467-043CD616AE6D

P433

Q34066537-859D481D-872D-4BB8-B100-48D7F136C1AC

P478

Q34066537-92D5DE01-A837-47E3-BB14-602EDA7AB6EB

P50

Q34066537-1AF472D8-D40C-48BD-BCC0-E21CAF89A1B5

Q34066537-3D394482-94BB-42DF-9822-F6E0CE84D410

P577

Q34066537-A3A1C05F-D4AC-4927-81A7-E2E68DA0A278

P698

Q34066537-314633F3-040E-424B-989F-9C0A2486050A

P932

Q34066537-414E973A-FDF7-472D-8094-4250769B320B

P356

QAD.0B013E3282F29478

P1433

P1476

Frequent polymorphism at drug ...... ease and reverse transcriptase

@en

P2093

Diane Rock-Kress

http://www.w3.org/2001/XMLSchema#string

Frank Maldarelli

http://www.w3.org/2001/XMLSchema#string

JoAnn Mican

http://www.w3.org/2001/XMLSchema#string

John M Coffin

http://www.w3.org/2001/XMLSchema#string

John W Mellors

http://www.w3.org/2001/XMLSchema#string

Joseph B Margolick

http://www.w3.org/2001/XMLSchema#string

Sarah Palmer

http://www.w3.org/2001/XMLSchema#string

Wei Shao

http://www.w3.org/2001/XMLSchema#string

P2860

CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice

Multiple sequence alignment with the Clustal series of programs

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.

Evolution of human immunodeficiency virus under selection and weak recombination.

In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects.

pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D.

New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma.

Substitutions in the reverse transcriptase and protease genes of HIV-1 subtype B in untreated individuals and patients treated with antiretroviral drugs.

Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays.

P304

497-501

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E3282F29478

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Michael A. Polis

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18301062

http://www.w3.org/2001/XMLSchema#string

P932

2921824

http://www.w3.org/2001/XMLSchema#string